Inozyme Pharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018
Selling, General & Admin	20.8	20.83	18.93	10.55	4.59	3.49
Research & Development	54.85	47.85	37.72	46.49	16.22	8.1
Operating Expenses	75.65	68.68	56.65	57.04	20.81	11.59
Operating Income	-75.65	-68.68	-56.65	-57.04	-20.81	-11.59
Interest Expense / Income	3.33	0.26	0	0	0	0
Other Expense / Income	-7.81	-1.88	-0.02	-0.62	-1.08	-4.63
Pretax Income	-71.17	-67.06	-56.62	-56.42	-19.72	-6.96
Net Income	-71.17	-67.06	-56.62	-56.42	-19.72	-6.96
Shares Outstanding (Basic)	52	38	24	11	1	1
Shares Outstanding (Diluted)	52	38	24	11	1	1
Shares Change	37.27%	60.30%	113.46%	832.81%	12.60%	-
EPS (Basic)	-1.37	-1.78	-2.40	-5.11	-16.67	-6.63
EPS (Diluted)	-1.37	-1.78	-2.40	-5.11	-16.67	-6.63
Free Cash Flow	-70.97	-58.17	-48.55	-36.54	-18.95	-9.7
Free Cash Flow Per Share	-1.37	-1.54	-2.06	-3.31	-16.02	-9.23
EBITDA	-66.51	-65.62	-55.57	-56.21	-19.64	-6.94
Depreciation & Amortization	1.33	1.18	1.05	0.22	0.08	0.03
EBIT	-67.84	-66.8	-56.62	-56.42	-19.72	-6.96

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).